PPARγ agonists, which regulate glucose and lipid metabolism and suppress inflammatory gene expression, have shown significant improvements in memory and cognition in AD patients, highlighting their therapeutic potential in AD treatment[26]. Here, PPARG is linked to Alzheimer disease.